+1 877 302 8632
+1 888 205 9894 (Toll-free)

SARS-CoV-2 Spike S2 Antikörper (C-Term) Primary Antibody

Reaktivität: SARS Coronavirus (SARS-CoV), SARS Coronavirus-2 (SARS-CoV-2) ELISA, IF, WB Wirt: Kaninchen Polyclonal
Pubmed (5)
Produktnummer ABIN1030641
Zzgl. Versandkosten $45.00
0.1 mg ABIN1030641
0.1 mg ABIN1030641
local_shipping Lieferung nach: Vereinigte Staaten von Amerika
Lieferung in 2 bis 3 Werktagen
  • Target
    SARS Coronavirus (SARS-CoV), SARS Coronavirus-2 (SARS-CoV-2)
    Dieser SARS-CoV-2 Spike S2 Antikörper ist unkonjugiert
    ELISA, Immunofluorescence (IF), Western Blotting (WB)
    Blocking Peptide
    Zu diesem Produkt passt das Blocking Peptide ABIN1382273.
    Predicted reactivity based on immunogen sequence: SARS-CoV Spike proteins: (100%)
    Affinity chromatography purified via peptide column
    Anti-SARS-CoV-2 (COVID-19, 2019-nCoV) Spike antibody was raised against a peptide corresponding to 20 amino acids near the carboxy terminus of SARS-CoV-2 (COVID-19, 2019-nCoV) Spike glycoprotein.
    The immunogen is located within the last 50 amino acids of SARS-CoV-2 (COVID-19, 2019-nCoV) Spike protein.
  • Applikationshinweise
    SARS-CoV-2 (COVID-19, 2019-nCoV) Spike antibody can be used for the detection of SARS-CoV-2 (COVID-19, 2019-nCoV) Spike protein in ELISA. It will detect 4 ng of free peptide at 1 μg/mL.
    Nur für Forschungszwecke einsetzbar
  • Format
    1 mg/mL
    The antibody is supplied in PBS containing 0.02% sodium azide.
    Sodium azide
    This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
    4 °C/-20 °C
    Informationen zur Lagerung
    Antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year.
    12 months
  • Magro, Mulvey, Berlin, Nuovo, Salvatore, Harp, Baxter-Stoltzfus, Laurence: "Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases." in: Translational research : the journal of laboratory and clinical medicine, Vol. 220, pp. 1-13, 2020 (PubMed).

    Mulvey, Magro, Ma, Nuovo, Baergen: "Analysis of complement deposition and viral RNA in placentas of COVID-19 patients." in: Annals of diagnostic pathology, Vol. 46, pp. 151530, 2020 (PubMed).

    Jan Pietschmann, Nadja Vöpel, Holger Spiegel, Hans-Joachim Krause, Florian Schröper: "Brief Communication: Magnetic Immuno-Detection of SARS-CoV-2 specific Antibodies" in: bioRxiv, 2020

    Nuovo, Tili, Suster, Matys, Hupp, Magro et al.: "Strong homology between SARS-CoV-2 envelope protein and a Mycobacterium sp. antigen allows rapid diagnosis of Mycobacterial infections and may provide specific anti-SARS-CoV-2 immunity via the BCG ..." in: Annals of diagnostic pathology, Vol. 48, pp. 151600, 2020 (PubMed).

    Funari, Chu, Shen: "Detection of antibodies against SARS-CoV-2 spike protein by gold nanospikes in an opto-microfluidic chip" in: Biosensors and Bioelectronics, 2020

  • Target
    Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak. The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection. The spike protein is the major target for neutralizing antibodies and vaccine development. The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19. The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein .
    NCBI Accession
Sie sind hier: